← Back to Search

Other

TMS for Decision-Making in Aging

N/A

Recruiting

Research Sponsored by University of Arizona

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Fluent in English or formal education in English starting from at least the age of 5

Montreal Cognitive Assessment (MoCA) > 25

Timeline

Screening 3 weeks

Treatment Varies

Follow Up between tms session 1 and tms session 2 (1-2 weeks)

Awards & highlights

Study Summary

This trialwill study the effect of TMS on explore-exploit behavior in younger & older adults, using cTBS to inhibit neural activity in the frontal pole & IFG to measure downstream effects on behavior.

Who is the study for?

Adults aged 18-30 or 65-74 with good cognitive health, no significant neurological or psychiatric conditions, and not on certain medications can join this study. They must be fluent in English, have a normal mood assessment score, and pass specific memory and cognitive screenings.Check my eligibility

What is being tested?

The trial tests how brain stimulation affects decision-making. Participants will undergo transcranial magnetic stimulation (TMS) targeting two brain areas: the frontal pole and IFG. The goal is to see if TMS changes their tendency to explore new options or exploit known ones.See study design

What are the potential side effects?

While the document doesn't list side effects explicitly for TMS, common ones include headache, scalp discomfort at the site of stimulation, lightheadedness, risk of seizure (though very rare), and hearing issues if ear protection isn't used during treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been fluent in English or educated in English since age 5.

Select...

My cognitive function score is above 25.

Select...

I am either 18-30 or 65-74 years old.

Select...

I do not have any major brain, mental health, or other medical issues affecting my thinking.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ between tms session 1 and tms session 2 (1-2 weeks)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~between tms session 1 and tms session 2 (1-2 weeks)

This trial's timeline: 3 weeks for screening, Varies for treatment, and between tms session 1 and tms session 2 (1-2 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Directed exploration

Random exploration

Trial Design

4Treatment groups

Experimental Treatment

Group I: Target: frontal pole; Order: vertex firstExperimental Treatment1 Intervention

In this arm the target stimulation site is the frontal pole, the control stimulation site is the vertex. Participants will receive the vertex stimulation in the first TMS session and frontal pole stimulation in the second TMS session.

Group II: Target: frontal pole; Order: frontal pole firstExperimental Treatment1 Intervention

In this arm the target stimulation site is the frontal pole, the control stimulation site is the vertex. Participants will receive the frontal pole stimulation in the first TMS session and vertex stimulation in the second TMS session.

Group III: Target: IFG; Order: vertex firstExperimental Treatment1 Intervention

In this arm the target stimulation site is the IFG, the control stimulation site is the vertex. Participants will receive vertex stimulation in the first TMS session and IFG stimulation in the second TMS session.

Group IV: Target: IFG; Order: IFG firstExperimental Treatment1 Intervention

In this arm the target stimulation site is the IFG, the control stimulation site is the vertex. Participants will receive IFG stimulation in the first TMS session and vertex stimulation in the second TMS session.

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor

514 Previous Clinical Trials

148,033 Total Patients Enrolled

1 Trials studying Healthy Aging

74 Patients Enrolled for Healthy Aging

National Institute on Aging (NIA)NIH

1,671 Previous Clinical Trials

28,016,823 Total Patients Enrolled

13 Trials studying Healthy Aging

1,314 Patients Enrolled for Healthy Aging

Media Library

Continuous theta burst transcranial magnetic stimulation (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05178381 — N/A

Healthy Aging Research Study Groups: Target: IFG; Order: vertex first, Target: frontal pole; Order: vertex first, Target: IFG; Order: IFG first, Target: frontal pole; Order: frontal pole first

Healthy Aging Clinical Trial 2023: Continuous theta burst transcranial magnetic stimulation Highlights & Side Effects. Trial Name: NCT05178381 — N/A

Continuous theta burst transcranial magnetic stimulation (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05178381 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research endeavor accommodate elderly participants?

"The requirements for being accepted into this clinical trial entails one to be aged between 18 and 80 years old. However, if the applicant is underaged or elderly there are 1 and 48 trials respectively that they can apply to."

Answered by AI

To what extent are individuals participating in this research?

"Indeed, the information provided on clinicaltrials.gov confirms that this medical trial is currently open for enrollment. Posted initially on October 1st 2022 and recently updated November 29th 2022, the study needs a total of 240 patients to be recruited from one centre."

Answered by AI

Am I eligible to partake in this research endeavor?

"Participants must display robust health and be aged between 18-80 to meet the requirements of this trial. Currently, a maximum of 240 people can take part in the study."

Answered by AI

Are there still opportunities to join this clinical trial?

"Yes, according to the information on clinicaltrials.gov, this medical trial is currently in search of participants. It was initially uploaded on October 1st 2022 and has seen its most recent update as of November 29th 2022. The study requires 240 patients from a single location for enrolment."

Answered by AI

Recent research and studies

NeuronJournal

Theta Burst Stimulation of the Human Motor Cortex

Huang, Ying-Zu, Mark J. Edwards, Elisabeth Rounis, Kailash P. Bhatia, and John C. Rothwell. 2005. “Theta Burst Stimulation of the Human Motor Cortex”. Neuron. Elsevier BV. doi:10.1016/j.neuron.2004.12.033.

Clinical NeurophysiologyJournal

Safety, Ethical Considerations, and Application Guidelines for the Use of Transcranial Magnetic Stimulation in Clinical Practice and Research

Rossi, Simone, Mark Hallett, Paolo M. Rossini, and Alvaro Pascual-Leone. 2009. “Safety, Ethical Considerations, and Application Guidelines for the Use of Transcranial Magnetic Stimulation in Clinical Practice and Research”. Clinical Neurophysiology. Elsevier BV. doi:10.1016/j.clinph.2009.08.016.

clinicaltrials.govStudy

Evaluating the Neurocomputational Mechanisms of Explore-Exploit Decision Making in Older Adults

Robert Wilson 2022. "Evaluating the Neurocomputational Mechanisms of Explore-Exploit Decision Making in Older Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05178381.

All > Transcranial Magnetic Stimulation